Allegro Ophthalmics Names Melvin Sarayba, MD, Vice President Of Clinical Affairs

Source: Allegro Ophthalmics

Tuesday, March 07, 2017 | Management/Leadership , Allegro Ophthalmics


Allegro Ophthalmics announced that Melvin Sarayba, MD, has joined the company as vice president of clinical affairs. In his new role, Dr. Sarayba is responsible for Allegro’s US and international clinical program for Luminate, which met its primary and secondary endpoints in the DEL MAR phase 2b clinical trial for diabetic macular edema (DME), the company announced in October, 2016.

An ophthalmic surgeon with an extensive clinical research background and two decades of product development and commercialization experience, Dr. Sarayba has worked for multiple successful ophthalmic companies, including IntraLase, AMO, WaveTec, LenSx Lasers, Alcon Laboratories and ClarVista Medical.At LenSx, he served as vice president of clinical affairs leading the company’s efforts on ophthalmic medical device product development, product improvement, and new applications.

Dr. Sarayba also has designed and led clinical trials at various stages of the life cycle. As the head of global medical affairs for the cataract franchise at Alcon, he was responsible for key clinical initiatives for the company’s entire cataract portfolio.  Dr. Sarayba completed his fellowship training at the University of California, Irvine.  He is a prolific innovator with 10 patents and has authored or co-authored numerous peer-reviewed publications.

“Melvin’s history of successfully running pivotal clinical trials for innovative startup companies like IntraLase and LenSx and for respected industry leaders like Alcon and AMO make him a valuable addition to the Allegro team," Hampar Karageozian, MSc, MBA, cofounder and chief executive officer, Allegro Ophthalmics, said in a company news release. “I am confident that Dr. Sarayba will be an enormous asset to Allegro and will continue to propel Luminate, which has thus far shown very promising efficacy and safety results in Phase 2 clinical trials across multiple indications, through trials and on to commercialization.”


Comments

You must be logged in to leave a comment.